美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Silexion Therapeutics Corp

1.56

-0.0200-1.27%

盘后：1.45-0.1100-7.05%18:57 EST

成交量：2.29万

成交额：3.59万

市值：487.76万

市盈率：-0.06

高：1.64

开：1.57

低：1.52

收：1.58

52周最高：26.70

52周最低：1.51

股本：312.66万

流通股本：275.35万

量比：1.04

换手率：0.83%

股息：- -

股息率：- -

每股收益(TTM):-25.2122

每股收益(LYR):-395.3595

净资产收益率：-771.23%

总资产收益率：-77.60%

市净率：0.70

市盈率(LYR):0.00

数据加载中...

总览公司新闻资讯公告

Silexion Therapeutics Corp盘中异动大幅下挫5.14%报1.66美元

Silexion Therapeutics获得德国卫生部门对其胰腺癌2/3期临床试验设计的积极反馈

Silexion Therapeutics 成功完成 Sil204 的毒理学研究，为胰腺癌的 2/3 阶段临床试验做好准备

Silexion Therapeutics Corp公布积极的人体细胞系数据，证实Sil204的泛KRAS活性，抑制率高达99.7%，并首次在胃癌中显示疗效

Silexion Therapeutics股价盘前暴涨235.3%，公司发布胰腺癌治疗积极临床前数据

Silexion Therapeutics：最新数据显示Sil204成功抵达胰腺癌转移的所有主要部位

Silexion Therapeutics公布积极临床前数据，显示Sil204经系统给药后可到达胰腺癌主要转移部位并发挥活性

Silexion Therapeutics宣布选定合同研究机构，为Sil204即将开展的2/3期临床试验提供支持

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/SLXN/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.56,"timestamp":1771621200000,"preClose":1.58,"halted":0,"volume":22864,"hourTrading":{"tag":"盘后","latestPrice":1.45,"preClose":1.56,"latestTime":"18:57 EST","volume":1362,"amount":2029.67,"timestamp":1771631877995,"change":-0.11,"changeRate":-0.070513,"amplitude":0.070513},"delay":0,"changeRate":-0.012658227848101276,"floatShares":2753490,"shares":3126642,"eps":-25.2122,"marketStatus":"休市中","change":-0.02,"latestTime":"02-20 16:00:00 EST","open":1.57,"high":1.6399,"low":1.5208,"amount":35916.9112704,"amplitude":0.07538,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-25.2122,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.58,"preHourTrading":{"tag":"盘前","latestPrice":1.5479,"preClose":1.58,"latestTime":"08:07 EST","volume":1842,"amount":3040.1931858,"timestamp":1771592842542,"change":-0.0321,"changeRate":-0.020316,"amplitude":0.189557},"postHourTrading":{"tag":"盘后","latestPrice":1.45,"preClose":1.56,"latestTime":"18:57 EST","volume":1362,"amount":2029.67,"timestamp":1771631877995,"change":-0.11,"changeRate":-0.070513,"amplitude":0.070513},"volumeRatio":1.0430847197337358},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":2753490,"roa":"-77.60%","roe":"-771.23%","lyrEps":-395.359461,"volumeRatio":1.0430847197337358,"shares":3126642,"dividePrice":0,"high":1.6399,"amplitude":0.07538,"preClose":1.58,"low":1.5208,"week52Low":1.51,"pbRate":"0.70","week52High":26.7,"institutionHeld":0,"latestPrice":1.56,"eps":-25.2122,"divideRate":0,"volume":22864,"delay":0,"ttmEps":-25.2122,"open":1.57,"prevYearClose":1.92,"prevWeekClose":1.59,"prevMonthClose":1.83,"prevQuarterClose":1.92,"fiveDayClose":1.58,"twentyDayClose":2.15,"sixtyDayClose":2.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1765861200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2026-02-20","current":-0.061875,"percent":0.234146,"low":-1.070842,"twenty":-0.591719,"median":-0.41963,"eighty":-0.125548,"high":-0.075397,"avg":-0.405996,"sd":0.24995,"marketCap":4940094},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-05","current":-1.070842,"twenty":-0.471245,"median":-0.259284,"eighty":-0.119953,"marketCap":9902075},{"date":"2025-12-12","current":-1.0279,"twenty":-0.478706,"median":-0.282158,"eighty":-0.120362,"marketCap":9504991},{"date":"2025-12-19","current":-0.821644,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"marketCap":7597740},{"date":"2025-12-26","current":-0.797975,"twenty":-0.491377,"median":-0.316599,"eighty":-0.121181,"marketCap":7378875},{"date":"2026-01-02","current":-0.6492,"twenty":-0.495368,"median":-0.386196,"eighty":-0.12159,"marketCap":6003152},{"date":"2026-01-09","current":-0.710063,"twenty":-0.504027,"median":-0.401489,"eighty":-0.122205,"marketCap":6565948},{"date":"2026-01-16","current":-0.825025,"twenty":-0.510588,"median":-0.409651,"eighty":-0.122955,"marketCap":7629006},{"date":"2026-01-23","current":-0.726969,"twenty":-0.515839,"median":-0.412313,"eighty":-0.12316,"marketCap":6722280},{"date":"2026-01-30","current":-0.662725,"twenty":-0.574408,"median":-0.414769,"eighty":-0.123296,"marketCap":6128218},{"date":"2026-02-06","current":-0.510569,"twenty":-0.606596,"median":-0.415025,"eighty":-0.12391,"marketCap":4721229},{"date":"2026-02-13","current":-0.534237,"twenty":-0.597129,"median":-0.417327,"eighty":-0.124456,"marketCap":4940094},{"date":"2026-02-20","current":-0.534237,"twenty":-0.591719,"median":-0.41963,"eighty":-0.125548,"marketCap":4940094}],"updateTime":1771732385421},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610620679","title":"Silexion Therapeutics Corp盘中异动 大幅下挫5.14%报1.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610620679","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610620679?lang=zh_cn&edition=fundamental","pubTime":"2026-02-11 01:34","pubTimestamp":1770744859,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日01时34分，Silexion Therapeutics Corp股票出现波动，股价急速下挫5.14%。截至发稿，该股报1.66美元/股，成交量2.9551万股，换手率0.95%，振幅6.86%。Silexion Therapeutics Corp股票所在的生物技术行业中，整体涨幅为0.14%。Silexion Therapeutics Corp公司简介：Silexion Therapeutics Corp 是一家临床阶段的肿瘤学生物技术公司，致力于发现和开发KRAS驱动癌症的专有治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211013419a6eb6aac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211013419a6eb6aac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","SLXN","BK4539","BK4139"],"gpt_icon":0},{"id":"1108369243","title":"Silexion Therapeutics获得德国卫生部门对其胰腺癌2/3期临床试验设计的积极反馈","url":"https://stock-news.laohu8.com/highlight/detail?id=1108369243","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108369243?lang=zh_cn&edition=fundamental","pubTime":"2025-12-02 21:01","pubTimestamp":1764680504,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics获得德国卫生部门对其胰腺癌2/3期临床试验设计的积极反馈","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"1186776790","title":"Silexion Therapeutics 成功完成 Sil204 的毒理学研究，为胰腺癌的 2/3 阶段临床试验做好准备","url":"https://stock-news.laohu8.com/highlight/detail?id=1186776790","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186776790?lang=zh_cn&edition=fundamental","pubTime":"2025-11-25 22:16","pubTimestamp":1764080200,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics 成功完成了 Sil204 的毒理学研究，这是一种下一代 RNA 静默疗法，为即将进行的胰腺癌 2/3 阶段临床试验做好了准备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"1183341465","title":"Silexion Therapeutics Corp公布积极的人体细胞系数据，证实Sil204的泛KRAS活性，抑制率高达99.7%，并首次在胃癌中显示疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1183341465","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183341465?lang=zh_cn&edition=fundamental","pubTime":"2025-09-30 20:40","pubTimestamp":1759236051,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp宣布公布积极的人体细胞系新数据，证实了其候选药物Sil204的泛KRAS活性。数据显示，该药物的抑制率高达99.7%，并首次在胃癌治疗中展现出积极效果。\n这项最新研究结果进一步验证了Sil204作为泛KRAS抑制剂的潜力，为该公司在肿瘤治疗领域的药物开发提供了重要支撑。特别值得关注的是，这是该药物首次在胃癌细胞中显示出治疗活性，为胃癌患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"1141650023","title":"Silexion Therapeutics股价盘前暴涨235.3%，公司发布胰腺癌治疗积极临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1141650023","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141650023?lang=zh_cn&edition=fundamental","pubTime":"2025-09-11 19:26","pubTimestamp":1757589977,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics股价盘前暴涨235.3%，公司发布胰腺癌治疗积极临床前数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"1172578975","title":"Silexion Therapeutics：最新数据显示Sil204成功抵达胰腺癌转移的所有主要部位","url":"https://stock-news.laohu8.com/highlight/detail?id=1172578975","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172578975?lang=zh_cn&edition=fundamental","pubTime":"2025-09-11 19:06","pubTimestamp":1757588764,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics：最新数据显示Sil204成功抵达胰腺癌转移的所有主要部位","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"1118879000","title":"Silexion Therapeutics公布积极临床前数据，显示Sil204经系统给药后可到达胰腺癌主要转移部位并发挥活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1118879000","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118879000?lang=zh_cn&edition=fundamental","pubTime":"2025-09-11 19:02","pubTimestamp":1757588575,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics近日公布了令人鼓舞的临床前研究数据，证实其候选药物Sil204在系统给药后能够有效到达胰腺癌的主要转移部位并展现出治疗活性。这一研究结果为该公司在胰腺癌治疗领域的药物开发进展提供了重要支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"1169989588","title":"Silexion Therapeutics宣布选定合同研究机构，为Sil204即将开展的2/3期临床试验提供支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1169989588","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169989588?lang=zh_cn&edition=fundamental","pubTime":"2025-09-04 21:25","pubTimestamp":1756992315,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics宣布选定合同研究机构，为Sil204即将开展的2/3期临床试验提供支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}